Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05034497 · ClinicalTrials.gov registry record · Phase 1
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
A Phase 1 study of Leptomeningeal Metastasis, sponsored by Plus Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 6
- Study locations
NCT05034497: Active Phase 1 study of Leptomeningeal Metastasis, sponsored by Plus Therapeutics.
NCT05034497 is a Phase 1 study of Leptomeningeal Metastasis that is active but no longer recruiting, run by Plus Therapeutics. The registered enrollment target is 18 participants, below the 58-participant average among 6 other Leptomeningeal Metastasis trials with a reported enrollment target (69% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05034497, a Phase 1 study of Leptomeningeal Metastasis, is active but no longer recruiting, sponsored by Plus Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).
Primary Outcome
Safety will be evaluated by the incidence of AEs and SAEs graded according CTCAE version 5.0.
Conditions Studied
Interventions
- DRUG 186RNL
Study Locations (6)
New York
- Northshore University Hospital - Manhasset
- Lenox Hill Hospital - New York
Texas
- Universiy of Texas Southwestern Medical Center - Dallas
- UT Health Science Center San Antonio / Mays Cancer Center - San Antonio
Illinois
- Northwestern Memorial Hospital Olson Pavilion - Chicago
Ohio
- Ohio State University Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
What the registry record for NCT05034497 still lists
NCT05034497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 58-participant average among 6 other Leptomeningeal Metastasis trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Leptomeningeal Metastasis appearing as the primary indexed condition, and to 1 intervention - of which 186RNL is the first listed.
NCT05034497 lists 6 locations in 4 states (New York, Texas, Illinois).
Frequently Asked Questions
What is clinical trial NCT05034497 about?
NCT05034497 is a clinical study titled "Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases". This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).
What is the current status of trial NCT05034497?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2021-12-06. Estimated completion is 2026-06-30.
What conditions does trial NCT05034497 study?
This clinical trial studies the following conditions: Leptomeningeal Metastasis.
What interventions are being tested in trial NCT05034497?
The interventions under investigation include: 186RNL (DRUG).
Who is sponsoring clinical trial NCT05034497?
This trial is sponsored by Plus Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05034497 being conducted?
This trial has 6 study locations across Illinois, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leptomeningeal Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
RECRUITING · Phase 1
-
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
RECRUITING · Phase 1
-
GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
ACTIVE NOT RECRUITING · Phase 1
-
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RECRUITING · Phase 2
-
Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI